Endonovo Therapeutics to Present at the SeeThruEquity 5th Annual Microcap Investor Conference in New York
(firmenpresse) - LOS ANGELES, CA -- (Marketwired) -- 04/13/16 -- (OTCQB: ENDV) ("Endonovo" or the "Company"), an innovative biotechnology company developing bioelectronic products and therapies for regenerative medicine, announced today that Endonovo Chairman & CEO, Alan Collier, will present a company and bioelectronics overview at the SeeThruEquity 5th Annual Microcap Investor Conference on May 31, 2016. The event will be held at Convene Conference Center at 730 3rd Avenue in New York City.
Endonovo Therapeutics, Inc. is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. Endonovo''s Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation, cell death and the promotion of regeneration. Endonovo''s Cytotronics™ platform provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies. The Company''s initial concentration is on the treatment of acute and chronic inflammatory conditions of the liver using its proprietary Immunotronics™ platform.
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company''s reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company''s estimates as of the date of the press release, and subsequent events and developments may cause the Company''s estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company''s estimates of its future financial performance as of any date subsequent to the date of this press release.
Endonovo Therapeutics, Inc.
Mr. Steven Barnes
Vice President of Investor Relations
(800) 701-1223, Ext. 108
Investors: Sign Up for Email Alerts on Endonovo
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.04.2016 - 06:34 Uhr
Sprache: Deutsch
News-ID 1427796
Anzahl Zeichen: 2192
contact information:
Contact person:
Town:
LOS ANGELES, CA
Phone:
Kategorie:
Alternative
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 116 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Endonovo Therapeutics to Present at the SeeThruEquity 5th Annual Microcap Investor Conference in New York
"
steht unter der journalistisch-redaktionellen Verantwortung von
Endonovo Therapeutics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
